诺和诺德(NVO)
icon
搜索文档
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
Investopedia· 2024-07-12 23:55
Key TakeawaysAmerican depositary receipts (ADRs) of Novo Nordisk rose in intraday trading Friday after an Oxford study showed the Danish company’s Ozempic diabetes drug was linked to lower rates of dementia.The drug also has been linked to a reduction in a range of mental problems, according to an article in The Lancet’s eClinicalMedicine journal.The study is the latest to show that semaglutide, the active ingredient in both Novo Nordisk’s Ozempic and its obesity medicine Wegovy, can treat more than diabete ...
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
ZACKS· 2024-07-12 01:11
Novo Nordisk (NVO) has rallied 38% in the year-to-date period compared with the industry’s 23.3% growth, as seen in the chart below. The stock has also outperformed the sector and the S&P 500. NVO is currently trading near the 52-week high. Novo Nordisk Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchNovo Nordisk, a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its GLP-1 agonist, semaglutide, which is approved as an Ozempic ...
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
ZACKS· 2024-07-12 00:31
Novo Nordisk (NVO) announced that it has received a complete response letter from the FDA for its biologics license application (“BLA”) for once-weekly basal insulin icodec.The BLA seeks approval for once-weekly basal insulin icodec for the treatment of diabetes mellitus. The application was submitted in April 2023.The FDA requested information related to the manufacturing process and the type 1 diabetes indication before it can complete the review of the application.Novo is evaluating the content of the CR ...
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
文章核心观点 - 美国FDA对诺和诺德公司的一种每周一次的基础胰岛素icodec的生物制品许可申请发出了完整回应信,要求公司在完成审查之前解决与制造工艺和1型糖尿病适应症相关的问题 [1][2][3] - 诺和诺德公司正在评估完整回应信的内容,并将与FDA密切合作以满足其要求,但预计无法在2024年内完成 [2][3] - 尽管FDA咨询委员会认为目前的数据不足以得出1型糖尿病的正面获益-风险评估,但公司仍相信每周一次的基础胰岛素icodec对需要基础胰岛素治疗的糖尿病患者具有潜力 [4] - 该产品已在欧盟、加拿大、澳大利亚、日本和瑞士获批用于1型和2型糖尿病治疗,在中国获批用于2型糖尿病治疗 [5] 公司概况 - 诺和诺德是一家领先的全球医疗保健公司,成立于1923年,总部位于丹麦 [6] - 公司的宗旨是通过开创性的科学突破、扩大药品获取、预防和最终治愈疾病来战胜严重的慢性疾病 [6] - 公司在80个国家拥有约66,000名员工,产品销往约170个国家,在纳斯达克哥本哈根和纽约证券交易所上市 [6]
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
Proactiveinvestors NA· 2024-07-09 23:26
About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...
Why Novo Nordisk Stock Is Slipping Today
The Motley Fool· 2024-07-02 23:54
文章核心观点 - 美国总统拜登和参议员桑德斯呼吁诺和诺德公司降低其糖尿病和肥胖药物的价格[1][2] - 拜登和桑德斯正在推动立法,将每年Medicare可进行价格谈判的处方药数量增加到至少50种[2] - 拜登和桑德斯指出诺和诺德公司对其重磅药物Ozempic和Wegovy收取"过高的价格"[2] 公司层面 - 目前这一提议对诺和诺德公司没有直接影响,因为在分裂的国会要通过这项法案存在挑战[3] - 但制药公司长期面临来自国会的压力,诺和诺德公司未来可能被迫降低Ozempic和Wegovy的价格[3] - 尽管估值较高,但诺和诺德公司的糖尿病和肥胖药物需求将持续增长,加上有前景的管线,仍是长期投资的不错选择[4]
How To Pick Top Pharma Stocks: Novo Nordisk And More
Seeking Alpha· 2024-07-02 23:20
DMP Analyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is complex and thorny. Moreover, it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators. This article begins a series of an ...
Novo Nordisk steps up ad spend to keep the weight-loss crown
Proactiveinvestors NA· 2024-07-02 18:34
文章核心观点 - 该公司是一家专注于提供金融新闻和在线广播的公司,拥有遍布全球主要金融中心的新闻团队 [1][2] - 公司专注于中小市值公司的报道,同时也关注蓝筹股、大宗商品和新兴技术等投资故事 [3][4] - 公司采用前瞻性的技术手段,包括使用自动化和软件工具,但所有内容仍由人工编辑和撰写 [5][6][7] 行业概况 - 公司拥有遍布全球主要金融中心的新闻团队,包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯等地 [2] - 公司报道范围涵盖生物科技、制药、采矿、天然资源、电池金属、石油天然气、加密货币和新兴电动车技术等领域 [4] 公司概况 - 公司由拥有三十多年从业经验的资深新闻记者和编辑领导,负责内容质量控制、编辑政策和内容生产 [1] - 公司每年制作5万篇实时新闻、专题文章和视频采访 [1] - 公司采用前瞻性的技术手段,包括使用自动化和软件工具,但所有内容仍由人工编辑和撰写 [5][6][7]
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's What You Need to Know.
The Motley Fool· 2024-06-30 21:15
Wegovy was just approved in China. Novo Nordisk (NVO -1.21%) has emerged as one of the biggest names in the pharmaceutical world thanks to its robust line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic, Rybelsus, Saxenda, and Wegovy. While Ozempic is approved by the Food and Drug Administration (FDA) to treat diabetes patients, its sibling medicine Wegovy is prescribed for obesity care. Just this week, Novo Nordisk received some very good news regarding Wegovy. Let's dig ...
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
ZACKS· 2024-06-28 06:51
In the latest market close, Novo Nordisk (NVO) reached $144.49, with a +0.57% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.3%. Prior to today's trading, shares of the drugmaker had gained 8.28% over the past month. This has outpaced the Medical sector's gain of 1.69% and the S&P 500's gain of 3.38% in that time. Market participants will be closely following the ...